Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
about
Intermittent preventive treatment of malaria in pregnant women and infants: making best use of the available evidenceIntermittent preventive treatment for malaria in children living in areas with seasonal transmissionHigh levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: a cross sectional survey of six regions in TanzaniaCost implications of improving malaria diagnosis: findings from north-eastern TanzaniaDuration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infantsIntermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trialThe cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan AfricaDeterminants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and childrenIntermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trialIntermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, UgandaProtective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trialEffect of transmission intensity on hotspots and micro-epidemiology of malaria in sub-Saharan Africa.Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance.Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren.Independent lineages of highly sulfadoxine-resistant Plasmodium falciparum haplotypes, eastern Africa.Intermittent preventive treatment for malaria in sub-saharan African: a halfway technology or a critical intervention?Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia.Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial.Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.Multiplicity of Plasmodium falciparum infection following intermittent preventive treatment in infants.Intermittent preventive treatment for malaria in infants: a decision-support tool for sub-Saharan AfricaIgG responses to Anopheles gambiae salivary antigen gSG6 detect variation in exposure to malaria vectors and disease risk.Anti-malarial drugs and the prevention of malaria in the population of malaria endemic areas.Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infantsIntermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combinationIs housing quality associated with malaria incidence among young children and mosquito vector numbers? Evidence from Korogwe, TanzaniaDrug resistance maps to guide intermittent preventive treatment of malaria in African infants.Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations.Cluster-randomized study of intermittent preventive treatment for malaria in infants (IPTi) in southern Tanzania: evaluation of impact on survival.Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in InfantsMefloquine in the nucleus accumbens promotes social avoidance and anxiety-like behavior in mice.Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal.Brokering the boundary between science and advocacy: the case of intermittent preventive treatment among infants.Monitoring antifolate resistance in intermittent preventive therapy for malaria.The economic costs of malaria in children in three sub-Saharan countries: Ghana, Tanzania and KenyaImpact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial.Intermittent preventive treatment against malaria: an update.Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum.Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa.Comparative effectiveness of malaria prevention measures: a systematic review and network meta-analysis.
P2860
Q21032450-C3457140-C5FA-4CDD-BBDA-1FF3D56C70F8Q21032527-E0077B45-529D-406B-9C28-634CF27EC0C9Q21033803-77902032-D771-4009-8A5B-BCDDDB3F8C9AQ28472525-F4D17649-20E0-4D01-8CC4-A1C9AE990EFBQ28473083-C37D3BBB-9454-467C-B34A-71D262949679Q28473566-0F68D2BE-DC36-489B-984A-46811E8BEB97Q28474404-87B89F87-31BB-4266-B9FC-38BA2750CA97Q28477679-9FF77B70-AFA9-4C64-9B81-CB6180D36EB7Q28481649-5DFF1C81-14F2-4C90-A3C0-B8388F48A59AQ28536733-95730F76-14CD-4DEA-886E-ABCCA20622C7Q28541598-9E7E4D64-714F-46BB-A312-94245343BB4CQ32174317-24BC121F-ED2E-4E4C-868C-F08E09BC6164Q33691573-7EFD04AC-3F37-4E79-8491-A748AACB0654Q33728165-D9019E5A-BB56-4421-A1BE-6DAFF8D4E668Q33816411-5B69A124-5CF0-4FD8-95C4-93CA7EE7CB93Q33817498-412AA7CF-FBFD-4EC9-A102-87485E378B61Q33950981-359D1277-E5D1-4949-A827-B64B8AAD0C6DQ33964491-06CEE5BF-6D18-4021-BF70-4CF417586743Q34043921-265DAD39-37B6-47D8-A061-F65BE26E0790Q34128601-1994D74D-5175-43A9-B7E3-813A8373C232Q34271078-CB9A689F-57A4-4449-A426-ACE18CE006EBQ34328747-3722EE4C-1861-4645-BA3B-929A42FEE73AQ34407217-FD3DCB4D-800B-4012-9814-9661E516F05FQ34764404-79986AD6-2288-4D2A-8DD9-08292C4571C8Q34809408-D1ADA682-911F-4EBC-BBBA-0F9046F64C9CQ35088141-62061BF1-2910-4400-AAA4-3104933D54A6Q35228689-154AD5FE-2300-4DAC-A7DF-D2DEAB1FADDBQ35532863-06D89D4B-2149-44B9-9A7E-81C19231E384Q35680383-CB2E3ABB-C285-4E1F-B01E-CDCCB34627A0Q35850290-A9E8E000-1E07-476C-9D60-1ACD3C35A2C1Q36377991-C83C8B70-AAAD-4674-AD4C-AE1D71933FA2Q37119559-ED3DF0A8-5483-4183-B17D-959E1014E884Q37122802-55106BD1-3772-4082-A687-33D6BA1BEF5AQ37260585-242938D1-62A7-4673-9E82-5502648F7F04Q37352140-262B0460-ECBE-4E5A-883F-96C9430C1413Q37726083-357E6A2A-CCE6-4F29-AFB4-5645F84D27D5Q37747411-8041F391-F55F-4CBA-9D24-0AC0F82B2B10Q38472391-72BF855D-D8A4-4E01-858B-C097A48A7BB8Q38636047-F7078A71-3C28-4471-BBA2-E308F8850441Q54247222-A25C6E63-078F-4117-A8E7-ACC892D594D9
P2860
Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Protective efficacy and safety ...... ind, placebo-controlled trial.
@en
Protective efficacy and safety ...... ind, placebo-controlled trial.
@nl
type
label
Protective efficacy and safety ...... ind, placebo-controlled trial.
@en
Protective efficacy and safety ...... ind, placebo-controlled trial.
@nl
prefLabel
Protective efficacy and safety ...... ind, placebo-controlled trial.
@en
Protective efficacy and safety ...... ind, placebo-controlled trial.
@nl
P2093
P50
P921
P1433
P1476
Protective efficacy and safety ...... ind, placebo-controlled trial.
@en
P2093
Frank W Mosha
Ilona Carneiro
Ramadhan Hashim
Roly D Gosling
Samwel Gesase
P304
P356
10.1016/S0140-6736(09)60997-1
P407
P577
2009-09-16T00:00:00Z